AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

Launching this month, Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well as for the prevention of Marek disease and infectious ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

Drugmakers have begun to roll-out their generic versions of diabetes drug Empagliflozin, on day one after the innovative blockbuster drug from Boehringer Ingelheim (BI) went off patent ...

On Tuesday, Boehringer Ingelheim’s Empagliflozin became off-patent in India. Major domestic drugmakers are expected to launch their generic versions soon. According to the company’s statement ...